Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ACLY | P53396 | 8/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664086 | 0.83 | GHSR (0.58) | GHSRLMNAACLYMAPTTP53 | |
| SCHEMBL4664239 | 0.82 | GHSR (0.57) | GHSRLMNAACLYMAPTUSP2 | |
| SCHEMBL14398048 | 0.82 | GHSR (0.57) | GHSRLMNAACLYMAPTUSP2 | |
| SCHEMBL13245980 | 0.82 | GHSR (0.57) | GHSRLMNAACLYMAPTUSP2 | |
| SCHEMBL13245976 | 0.79 | GHSR (0.56) | GHSRLMNAACLYMAPTUSP2 | |
| SCHEMBL14398049 | 0.79 | GHSR (0.56) | GHSRLMNAACLYMAPTUSP2 | |
| SCHEMBL13245992 | 0.79 | GHSR (0.56) | GHSRLMNAACLYMAPTUSP2 | |
| SCHEMBL4801734 | 0.79 | GHSR (1.00) | GHSR | |
| SCHEMBL4801742 | 0.79 | GHSR (1.00) | GHSR | |
| SCHEMBL2992486 | 0.79 | GHSR (0.55) | GHSRLMNAACLYMAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179168-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | BLANEY EMMA LOUISE | 2010-07-15 | — | — | US | disclosed |
| EP-2007716-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007118852-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179168-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | GHSR 1/4885LMNA 4700/4885ACLY 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.